Chris McHugh Joins Zeus as Senior Vice President of Integrated Supply Chain

Zeus, a world leader in polymer extrusion and catheter manufacturing, is pleased to announce the appointment of Chris McHugh as the Senior Vice President of Integrated Supply Chain, a newly created role. McHugh is a pivotal addition to the leadership team, overseeing end-to-end operations across Zeus’ network of manufacturing facilities.

In this critical role, Chris McHugh will drive operational improvements across the company’s global network, focusing on embedding best-in-class operational excellence, safety, and efficiency principles throughout the organization. He will support the company’s growth objectives by establishing strong operating system processes and standards across the organization, developing and sustaining robust customer relationships, and building, managing, and developing a disciplined, focused, and outcomes-driven operations team with a culture of continuous improvement.

“We are confident that Chris’s leadership and vision will significantly contribute to our operational success and help to accelerate our growth trajectory,” says CEO Paddy O’Brien. “His addition to our team underscores our commitment to excellence and innovation in our supply chain operations and, ultimately, delivering exceptional value to our customers.”

Chris McHugh brings extensive experience in operations management, with a proven track record of leading high-performing teams and implementing transformative initiatives. Most recently, he served as Vice President of Operations at Cadence, Inc., a full-service medical device manufacturer and supplier. His expertise in optimizing processes and driving operational efficiency will be invaluable as Zeus expands its capabilities.

McHugh holds a Bachelor of Science in Mathematics and Physics from Michigan Technological University, a Master of Science in Electrical Engineering from the University of Michigan – Ann Arbor, and a postgraduate executive education in International Business from Columbia Business School.

“I am honored to join Zeus and contribute to its long-standing legacy of innovation and excellence,” said McHugh. “I look forward to working with this talented team to optimize our business processes and operational network to deliver world-class products and customer satisfaction.”

SourceZeus

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version